Loading
Life sciences · Journal article
BMC Cancer · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Breast cancer precision therapy faces drug delivery and response prediction challenges. Ultrasound micro/nanobubble platforms integrate theranostic functions but lack consistent evidence. A scoping review following the Arksey and O’Malley framework and Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines systematically searched PubMed, Web of Science, and Embase (January 2010-March 2026), screened 2,086 records and analyzed 38 studies on ultrasound-triggered microbubble/nanobubble platforms. It mapped evidence in imaging, local delivery and immunotherapy, and proposed their optimal role as immunotherapy delivery sensitization modules.